AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01769664
Drug: Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
Trial: NCT01769664
Drug: Duac® Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel) applied once a day in the evening for 77 days (11 weeks)
Trial: NCT01769664
Drug: Placebo Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
Trial: NCT02882438
Drug: infected group
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo Biloba in different dosage forms
Trial: NCT02882438
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo without Ginkgo Biloba
Trial: NCT01813201
Drug: Saline isotonic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline isotonic solution (placebo)intramuscular,administered at inclusion and every 12 weeks for 9 months (4 dose)
Trial: NCT01602601
Drug: GSK2788723
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2788723 is being developed by JCR and GSK for the treatment of Hunter syndrome
Trial: NCT02584452
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraoperative opioid should be limited to no more than 150mcg of fentanyl.
Trial: NCT01107392
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
Trial: NCT00654225
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02689206
Drug: GSK1278863
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.
Trial: NCT02689206
Drug: GSK1278863 matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1278863 matching placebo will be supplied as a round, biconvex, 10 mm white film coated tablet.
Trial: NCT04528550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Included patients will receive the same amount of saline through lumbar injection.
Trial: NCT00000401
Drug: Oral bovine type II collagen
RxNorm normalized name: bovine type II collagen (tracheal cartilage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug can be interrupted or stopped for suspected adverse events.
Trial: NCT01013324
Drug: XL147 (SAR245408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosed as capsules taken orally daily
Trial: NCT01415297
Drug: NKP-1339
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKP-1339 is administered as a 30-90 minute IV infusion (based on volume to be infused) on days 1, 8, and 15 of a 28 day cycle.
Trial: NCT00414323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01232127
Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, 10 days
Trial: NCT01232127
Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, 7 days
Trial: NCT03162796
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo as SC injection.
Trial: NCT02720523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; Oral
Trial: NCT01632592
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo given by injection 2mg subcutaneously daily
Trial: NCT00333411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01642056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03522935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous.
Trial: NCT03734926
Drug: ZSP1241
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1241 tablets for oral administration.
Trial: NCT00182078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo was administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the placebo was tapered at a rate of 25mg every 3 days until it was discontinued.
Trial: NCT00532311
Drug: Stable statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and stable statin therapy for up to 12 weeks.
Trial: NCT03180333
Drug: PNA
RxNorm normalized name: DPNase
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03180333
Drug: PNA placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01875393
Drug: TOOKAD® Soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The VTP procedure will consist of a single, 10 minute infusion of 4mg/kg TOOKAD® Soluble. The drug will be activated by laser light at 753nm, with a fixed energy of 200Joules/cm, and a fixed power of 150mWatts/cm, delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance.
Trial: NCT04393597
Drug: DWJ1458 (fed)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects take single dose of DWJ1458 after high-fat diet
Trial: NCT02270632
Drug: F8IL10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F8IL10 will be administered once a week for 8 weeks (or until withdrawn from the study).
Trial: NCT03376139
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
Trial: NCT00143624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See detailed description.
Trial: NCT03789123
Drug: Estradiol valerate/dienogest
RxNorm normalized name: Estradiol Valerate and Estradiol Valerate/Dienogest KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The effects of drugs given for endometrioma and contraception will be observed on ovarian reserve, endometrioma size and pain score.
Trial: NCT03001193
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00631813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bid
Trial: NCT03114111
Drug: aminolevulinic acid (ALA)
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03114111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01279291
Drug: pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. PLD will be administered weekly at a dose of 40 mg/m2.
Trial: NCT00375505
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00375505
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01393795
Drug: Tegaderm
RxNorm normalized name: Tegaderm 4x4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active drug
Trial: NCT04061824
Drug: Olostar Tab (olmesartan/rosuvastatin FDC(fixed dose combination))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In intervention group, patients had a pill of fixed-dose combination of Olmesartan medoxomil and Rosuvastatin, rather taking separated two pills.
Trial: NCT04061824
Drug: Two separated drugs(ARB(Angiotensin Ⅱ receptor blocker) and statin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In control group, patients had two separated pills for hypertension and dyslipidemia. One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin, Pravastatin, Fluvastatin and Atorvastatin/Ezetimibe).
Trial: NCT02473094
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 825mg/m2 bid, D1-D5 q7d
Trial: NCT02473094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo up to 2500mg/d
Trial: NCT02069821
Drug: combination administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)
Trial: NCT01185951
Drug: Topical NO
RxNorm normalized name: thickening agent, topical no.1 TOPICAL LIQUID (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nitroglycerine (Nitrolingualspray(R)) 2x2 hubs per day over 6 months daily on the painful tendon
Trial: NCT00500461
Drug: GSK233705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK233705 will be available as IV infusion and oral solution containing Cellobiose octaacetate.
Trial: NCT00460460
Drug: AZD4877
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03645278
Drug: SHR0532
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending dose oral adminstration
Trial: NCT03645278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending dose oral administration
Trial: NCT00803595
Drug: CS-8958
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-8958 powder 20 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
Trial: NCT00803595
Drug: CS-8958
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-8958 powder 40 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
Trial: NCT04118075
Drug: PT-CY-FK +/-ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.
Trial: NCT01163305
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy
Trial: NCT04304053
Drug: Treatment and prophylaxis
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cases will be offered a therapeutic regimen hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7~Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7.
Trial: NCT00792740
Drug: ITF2357
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITF2357 was administered as hard gelatin capsules for oral administration at the dose strength of 50 mg. Capsules were administered as follow: one capsule in the morning and one in the evening.
Trial: NCT02798744
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for the duration of the study (24 weeks)
Trial: NCT00055926
Drug: CP-724,714
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04124094
Drug: Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
Trial: NCT04124094
Drug: Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations in one study period
Trial: NCT01915537
Drug: Classic DMARDs treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classic DMARDs treatment: combination of 2 or 3 drugs, 2-drugs combination is MTX with LEF or Thunder God Vine, 3-drugs combination is MTX with HCQ and LEF or Thunder God Vine for total 30 weeks.~Effective dose: MTX: 10-15mg per week; LEF: 20mg per day; HCQ: 200-400 mg per day; Thunder God Vine: 40-60 mg per day; It recommended that the maintain regimen is MTX with HCQ or LEF after remission for a period of time.
Trial: NCT04590937
Drug: CRESTOR®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT02259361
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
Trial: NCT03323346
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed.~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper.
Trial: NCT01272830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two capsules taken twice daily with meals
Trial: NCT01272830
Drug: Apatone®B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two capsules taken twice daily with meals
Trial: NCT04590937
Drug: Lenoxin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT04590937
Drug: MetfoLiquid GeriaSan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT00777595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled solution, single dose of placebo
Trial: NCT04590937
Drug: Lasix®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT02216916
Drug: HM781-36B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01530503
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months
Trial: NCT04054921
Drug: PTG-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTG-300 is a hepcidin Mimetic
Trial: NCT03375645
Drug: Any oral opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency department patients who receive a prescription for an oral opioid
Trial: NCT00625391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg medicinal starch pills daily
Trial: NCT01958775
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00625391
Drug: Green Tea Polyphenols (GTP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg green tea polyphenols daily
Trial: NCT00625391
Drug: Placebo+Tai Chi (TC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg medicinal starch daily and Tai Chi (3x/week) for 24 weeks
Trial: NCT01405963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered in a 1-hour intravenous infusion
Trial: NCT00891202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAP: Matching placebo capsule once daily on Day 1 followed by matching placebo capsule BID from Day 2 through Week 39. LTTP: Participants of the placebo arm in PAP who completed PAP were included in LTTP and received eliglustat tartrate from Day 1 (post Week 39) up to Week 312. Day 1 (post Week 39) was considered as baseline for LTTP. On Day 1, participants received eliglustat tartrate capsule 50 mg BID orally until Week 43 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 47, then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if \>=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.
Trial: NCT01186887
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
Trial: NCT01186887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
Trial: NCT01795976
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide 60mg/kg/day day -7 and day -6
Trial: NCT02656394
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo topical gel
Trial: NCT00479102
Drug: Ferripel-3 - iron polysaccharide complex for prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01760616
Drug: Huaier Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huaier Granule is a Chinese medicine, specifications: 20g / bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd..
Trial: NCT00475085
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00343005
Drug: AMA1-C1/alhydrogel Malaria Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02453750
Drug: Hypersaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer. Sputum production (with cough) will be attempted post inhalation. A maximum of 3 hypertonic saline inhalations will be attempted if inhalation does not generate a productive cough. If sputum induction is not successful and the FEV1 falls \<10%, the concentration of inhaled hypertonic saline will increase from 3 to 4%. If 5 mls of 4% hypertonic saline inhaled for 7 minutes does not produce a productive cough we will proceed to 5%. If 5 mls of 5% hypertonic saline inhaled for 7 minutes does not produce a productive cough the test is complete and the sample is labelled 'no sputum collected'. If FEV1 falls \>10%, the previous step will be repeated.
Trial: NCT03974932
Drug: HTX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-acting local anesthetic. Dose 1.
Trial: NCT03974932
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NSAID.
Trial: NCT03974932
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic.
Trial: NCT03974932
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NSAID.
Trial: NCT03974932
Drug: +/- Bupivacaine HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic.
Trial: NCT03974932
Drug: HTX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-acting local anesthetic. Dose 2.
Trial: NCT01900522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITI-214 Matching Placebo Oral Solution
Trial: NCT05107063
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine initiation dose was 10 mg, 20 mg or 40 mg single dose once daily. Depending on patient response, dose could have been increased up to 40 mg. Maintenance dose was 10-40 mg once daily.
Trial: NCT03950544
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tigecycline and meropenem
Trial: NCT01905943
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 250 mg/m\^2 I.V. over 15-30 minutes qd Day 1-3 or Cyclophosphamide 250 mg/m\^2 p.o. QD Day 1-3 in fit participants only.
Trial: NCT00416494
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
Trial: NCT00416494
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort